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Glyphosate [N-(phosphonomethyl)glycine],
commonly sold in the commercial formula-
tion named Roundup (Monsanto Company,
St. Louis, MO), has been a frequently used
herbicide on both cropland and noncropland
areas of the world since its introduction in
the 1970s (Williams et al. 2000). Roundup is
a combination of the active ingredient and
other chemicals, including a surfactant (poly-
oxyethyleneamine) that enhances the spread-
ing of spray droplets when they contact
foliage. Glyphosate is a broad-spectrum her-
bicide of which the primary mechanism is
inhibition of the enzyme 5-enolpyruvoyl-
shikimate 3-phosphate synthase, which is
essential for the formation of aromatic amino
acids in plants (Steinrucken and Amrhein
1980). Because this speciﬁc biologic pathway
operates only in plants and microorganisms,
the mechanism is not considered to be a risk
for humans. Nevertheless, genotoxic, hor-
monal, and enzymatic effects in mammals
have been reported (Bolognesi et al. 1997;
Daruich et al. 2001; El Demerdash et al.
2001; Hietanen et al. 1983; Lioi et al. 1998a,
1998b; Olorunsogo et al. 1979; Peluso et al.
1998; Walsh et al. 2000; Yousef et al. 1995).
Results from genotoxicity studies of
glyphosate have been conﬂicting. Glyphosate
did not show any genotoxic activity in a 
battery of assays (Garry et al. 1999; Grisolia
2002; Li and Long 1988; Wildeman and
Nazar 1982). However, other studies observed
that glyphosate treatment of human lympho-
cytes in vitro resulted in increased sister chro-
matid exchanges (Bolognesi et al. 1997),
chromosomal aberrations (Lioi et al. 1998b),
and indicators of oxidative stress (Lioi et al.
1998b). Some studies found slightly greater
toxicity of the Roundup formulation com-
pared with glyphosate, in terms of both acute
toxicity (Folmar et al. 1979; Martinez et al.
1990; Mitchell et al. 1987) and genotoxicity
(Bolognesi et al. 1997; Vigfusson and Vyse
1980). Roundup was associated with increased
DNA adducts in mice (Peluso et al. 1998) and
a weak mutagenic effect in the Salmonella assay
(Kale et al. 1995; Moriya et al. 1983; Rank
et al. 1993), whereas glyphosate alone did not
show these effects. Chronic feeding studies of
glyphosate have not provided evidence of a
carcinogenic effect in mice or rats (Williams
et al. 2000).
The U.S. Environmental Protection
Agency (U.S. EPA 1993) and the World
Health Organization (WHO 1994) reviewed
the toxicology data on glyphosate and con-
cluded that glyphosate is not mutagenic or
carcinogenic. The U.S. EPA classified
glyphosate as category E, indicating “evidence
of noncarcinogenicity for humans” (U.S.
EPA 1993). Despite this conclusion, three
recent case–control studies suggested an asso-
ciation between reported glyphosate use and
the risk of non-Hodgkin lymphoma (NHL)
(De Roos et al. 2003b; Hardell and Eriksson
1999; Hardell et al. 2002; McDuffie et al.
2001). Considering the widespread and fre-
quent use of glyphosate in both the United
States and the rest of the world, ongoing risk
assessment is of importance. We studied site-
specific cancer incidence associated with
glyphosate use among pesticide applicators in
the Agricultural Health Study (AHS) cohort.
Materials and Methods
Cohort enrollment and follow-up. The AHS is
a prospective cohort study in Iowa and North
Carolina, which includes 57,311 private and
commercial applicators who were licensed to
apply restricted-use pesticides at the time of
enrollment. Recruitment of the applicators
occurred between 1993 and 1997 (Alavanja
et al. 1996). Cohort members were matched
to cancer registry files in Iowa and North
Carolina for case identification and to the
state death registries and the National Death
Index (National Center for Health Statistics
1999) to ascertain vital status. Incident cancers
were identified for the time period from the
date of enrollment until 31 December 2001
and were coded according to the International
Classiﬁcation of Diseases, 9th Revision (WHO
1977). If cohort members had moved from the
state, they were censored in the year they left.
The median time of follow-up was 6.7 years.
Exposure assessment. Using a self-adminis-
tered enrollment questionnaire, we collected
comprehensive-use data on 22 pesticides,
ever/never use information for 28 additional
pesticides, and general information on pesticide
application methods, personal protective equip-
ment, pesticide mixing, and equipment repair.
Data were also collected on basic demographic
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Glyphosate is a broad-spectrum herbicide that is one of the most frequently applied pesticides in
the world. Although there has been little consistent evidence of genotoxicity or carcinogenicity
from in vitro and animal studies, a few epidemiologic reports have indicated potential health
effects of glyphosate. We evaluated associations between glyphosate exposure and cancer incidence
in the Agricultural Health Study (AHS), a prospective cohort study of 57,311 licensed pesticide
applicators in Iowa and North Carolina. Detailed information on pesticide use and other factors
was obtained from a self-administered questionnaire completed at time of enrollment
(1993–1997). Among private and commercial applicators, 75.5% reported having ever used
glyphosate, of which > 97% were men. In this analysis, glyphosate exposure was deﬁned as a) ever
personally mixed or applied products containing glyphosate; b) cumulative lifetime days of use, or
“cumulative exposure days” (years of use × days/year); and c) intensity-weighted cumulative expo-
sure days (years of use × days/year × estimated intensity level). Poisson regression was used to esti-
mate exposure–response relations between glyphosate and incidence of all cancers combined and
12 relatively common cancer subtypes. Glyphosate exposure was not associated with cancer inci-
dence overall or with most of the cancer subtypes we studied. There was a suggested association
with multiple myeloma incidence that should be followed up as more cases occur in the AHS.
Given the widespread use of glyphosate, future analyses of the AHS will allow further examination
of long-term health effects, including less common cancers. Key words: cancer, cohort study, farm-
ing, glyphosate, pesticide. Environ Health Perspect 113:49–54 (2005). doi:10.1289/ehp.7340
available via http://dx.doi.org/ [Online 4 November 2004]and lifestyle factors. Applicators who com-
pleted this questionnaire were given a self-
administered take-home questionnaire, which
contained additional questions on occupational
exposures and lifestyle factors. The question-
naires are available from the AHS website
(National Institutes of Health 2004).
We constructed three glyphosate exposure
metrics for this analysis: a) ever personally
mixed or applied products containing
glyphosate (ever/never); b) cumulative lifetime
days of use, or “cumulative exposure days”
(years of use × days per year, categorized in
tertiles among users: 1–20, 21–56, 57–2,678);
and c) intensity-weighted cumulative exposure
days (years of use × days per year × intensity
level, categorized in tertiles: 0.1–79.5,
79.6–337.1, 337.2–18,241). Tertiles were
chosen a priori as the cut points with which to
categorize exposure data, to avoid sparse data
for rare cancers in the high-exposure cate-
gories. Intensity levels were estimated using
questionnaire data from enrollment and mea-
surement data from the published pesticide
exposure literature, as follows: intensity level =
[(mixing status + application method + equip-
ment repair status) × personal protective
equipment use] (Dosemeci et al. 2002).
Data analysis. Persons whose ﬁrst primary
cancer occurred before the time of enrollment
(n = 1,074) were excluded from analyses, as
were subjects who were lost to follow-up or
otherwise did not contribute any person-time
(n = 298) and applicators who did not provide
any information on age (n = 7) or whether
they had ever used glyphosate (n = 1,678).
After exclusions, 54,315 subjects were avail-
able for inclusion in the age-adjusted analyses
of cancer incidence in relation to glyphosate
use; however, other analyses contained fewer
observations because of missing data for dura-
tion and frequency of glyphosate use or for
covariates.
We compared certain baseline characteris-
tics among three types of pesticide applicators:
a) those applicators who never personally used
glyphosate; b) applicators with the lowest
glyphosate exposure, defined as being in the
lowest tertile of cumulative exposure days; and
c) those with higher glyphosate exposure,
deﬁned as being in the middle or highest ter-
tile of cumulative exposure days. The purpose
of the comparison was to identify potential
confounders of glyphosate exposure–disease
associations for the various analyses we con-
ducted. Differences between the exposure
groups were tested using the chi-square statis-
tics and associated p-values.
Poisson regression analyses were carried out
for all cancers combined and specific cancer
sites to estimate rate ratios (RRs) and 95%
confidence intervals (CIs) associated with
glyphosate exposure metrics; the effect of each
metric was evaluated in a separate model for
each cancer. We analyzed tertile exposure vari-
ables in separate models using either the lowest-
tertile–exposed or never-exposed subjects as the
reference category. We investigated specific
cancer sites for which there were at least
30 cases with sufﬁcient information for inclu-
sion in age-adjusted analyses. These cancers
were then evaluated for all the exposure metrics
and in adjusted analyses, despite smaller num-
bers of cases upon further adjustment. For each
exposure metric, RRs were adjusted for demo-
graphic and lifestyle factors, including age at
enrollment (continuous), education (dichoto-
mous: ≤ high school graduate or GED/educa-
tion beyond high school), pack-years of
cigarette smoking [indicator variables: never,
pack-years at or below the median (12 pack-
years), pack-years above the median], alcohol
consumption in the past year [indicator vari-
ables: none, frequency at or below the median
(72 drinks), frequency above the median], fam-
ily history of cancer in first-degree relatives
(dichotomous: yes/no), and state of residence
(dichotomous: Iowa/North Carolina). There
was insufﬁcient variability in sex or applicator
type to adjust for these factors.
Potential confounding from exposure to
other pesticides was explored by adjusting for
the five pesticides for which cumulative-
exposure-day variables were most highly associ-
ated with glyphosate cumulative exposure days
[(2,4-dichlorophenoxy)acetic acid (2,4-D),
alachlor, atrazine, metolachlor, trifluralin];
these pesticide exposures were coded as vari-
ables indicating never, low, and high, with the
split between low and high as the median of
their cumulative exposure days. Additionally,
of the pesticides for which only ever/never use
Article | De Roos et al.
50 VOLUME 113 | NUMBER 1 | January 2005 • Environmental Health Perspectives
Table 1. Selected characteristics of applicators in the AHS by glyphosate exposure, based on data from
the enrollment questionnaire (1993–1997).a
Never exposed Lowest exposed Higher exposed
(n = 13,280) (n = 15,911)b (n = 24,465)c
Characteristic No. (%) No. (%) No. (%)
State of residence
Iowa 9,987 (75.2) 9,785 (61.5) 15,336 (62.7)
North Carolina 3,293 (24.8) 6,126 (38.5) 9,129 (37.3)
Age (years)
< 40 2,279 (17.2) 2,226 (14.0) 4,190 (17.1)
40–49 3,420 (25.8) 4,279 (26.9) 7,899 (32.3)
50–59 2,989 (22.5) 3,931 (24.7) 6,035 (24.7)
60–69 2,715 (20.4) 3,266 (20.5) 3,997 (16.3)
70 1,877 (14.1) 2,209 (13.9) 2,344 (9.6)
Sex
Male 12,778 (96.2) 15,505 (97.5) 23,924 (97.8)
Female 502 (3.8) 406 (2.6) 541 (2.2)
Applicator typed
Private 12,067 (90.9) 15,008 (94.3) 21,938 (89.7)
Commercial 1,213 (9.1) 903 (5.7) 2,527 (10.3)
Education
High school graduate or GED 8,898 (68.7) 8,997 (57.9) 11,975 (50.1)
Beyond high school 4,060 (31.3) 6,530 (42.1) 11,936 (49.9)
Smoking history
Never 7,298 (57.3) 8,241 (53.2) 12,751 (53.7)
≤ 12 pack-years 2,866 (22.5) 3,597 (23.2) 5,572 (23.5)
> 12 pack-years 2,567 (20.2) 3,643 (23.5) 5,439 (22.9)
Alcohol consumption in past year
None 4,087 (32.7) 5,352 (35.6) 7,023 (29.8)
≤ 6 drinks/month 4,461 (35.7) 5,291 (35.2) 8,149 (34.5)
> 6 drinks/month 3,936 (31.5) 4,387 (29.2) 8,422 (35.7)
Family history of cancer
No 8,701 (65.5) 9,520 (59.8) 14,668 (60.0)
Yes 4,579 (34.5) 6,391 (40.2) 9,797 (40.0)
Use of other common pesticides
2,4-D 7,030 (53.3) 11,879 (75.2) 20,699 (85.1)
Alachlor 4,896 (39.7) 7,321 (50.9) 13,790 (59.7)
Atrazine 7,707 (58.5) 10,533 (66.6) 18,237 (75.0)
Metolachlor 3,890 (31.6) 6,172 (43.1) 12,952 (56.2)
Triﬂuralin 4,239 (34.0) 7,109 (49.7) 14,675 (63.5)
Carbaryl 4,110 (33.7) 8,515 (58.1) 15,139 (64.8)
Benomyl 510 (4.3) 1,418 (9.9) 3,391 (14.8)
Maneb 492 (4.1) 1,412 (9.9) 2,929 (12.9)
Paraquat 1,067 (9.0) 3,021 (21.2) 8,031 (35.2)
Diazinon 1,906 (16.0) 4,615 (32.4) 9,107 (40.0)
aIncludes observations for subjects included in age-adjusted Poisson regression models of cancer incidence (n = 54,315).
bLowest tertile of cumulative exposure days. cHighest two tertiles of cumulative exposure days; the sum of the three ter-
tiles of cumulative exposure days (n = 40,376) does not equal the total number of subjects who reported having ever used
glyphosate (n = 41,035) because of missing data on duration and frequency of use. d“Private” refers primarily to individual
farmers, and “commercial” refers to professional pesticide applicators.information was available, we adjusted for the
ﬁve pesticides that were most highly associated
with ever use of glyphosate (benomyl, maneb,
paraquat, carbaryl, diazinon). Where inclusion
of all 10 other pesticides in a model changed a
glyphosate exposure estimate by at least 20%
(compared with a model restricted to the same
observations), these results were presented as
the ﬁnal results for that cancer; otherwise, esti-
mates adjusted only for demographic and
lifestyle factors are presented.
Tests for trend across tertiles were con-
ducted by creating a continuous variable with
assigned values equal to the median value of
cumulative exposure days (or intensity-
weighted exposure days) within each tertile;
the p-value for the trend test was that from
the Poisson model coefﬁcient for this contin-
uous variable. We considered p-values < 0.10
as indicative of a trend.
Additional analyses were conducted for
cancers for which we observed elevated RRs,
and for NHL because of its association with
glyphosate in previous studies. These included
analyses stratiﬁed by state and analyses across
quartiles and quintiles (where numbers
allowed) of exposure days metrics.
Results
Selected characteristics of the glyphosate-
exposed and never-exposed applicators are pre-
sented in Table 1. Among 54,315 subjects
included in age-adjusted analyses, 41,035
(75.5%) reported having ever personally mixed
or applied products containing glyphosate, and
13,280 (24.5%) did not. The cohort, both
exposed and never exposed, was composed of
primarily of male, middle-aged, private appli-
cators. This is a population with relatively low
smoking prevalence; in both the exposed and
never-exposed groups, more than half of the
subjects reported that they had never smoked.
Significant differences (p < 0.05) existed
between never-exposed and lowest-exposed
subjects for all of the characteristics in Table 1.
Lowest- and higher-exposed subjects (p < 0.05)
also differed on several factors, the most
notable being that higher-exposed subjects
were more likely to be commercial applicators,
to have consumed greater amounts of alcohol
in the past year, and to have used other speciﬁc
pesticides. However, lowest- and higher-
exposed subjects were similar to each other
(p ≥ 0.05) in characteristics including smoking
and family history of cancer in a first-degree
relative. In addition, lowest- and higher-
exposed subjects were more similar to each
other than to their never-exposed counterparts
(by qualitative comparison of percentages only)
in factors including North Carolina residence,
education beyond high school, and use of
other pesticides. Because of relative similarities
between lowest- and higher-exposed in factors
associated with socioeconomic status and other
exposures, we decided to conduct some analy-
ses using lowest-exposed rather than never-
exposed applicators as the reference group, in
order to avoid residual confounding by unmea-
sured covariates. However, we decided a priori
that any association should be apparent regard-
less of which reference group was used.
RRs for the association of all cancers com-
bined and specific cancers with having ever
used glyphosate are presented in Table 2. RRs
adjusted for age only are presented, as well as
RRs adjusted for demographic and lifestyle
factors and, in some cases, for other pesticides.
The incidence of all cancers combined was not
associated with glyphosate use, nor were most
speciﬁc cancers. There was an 80% increased
risk of melanoma associated with glyphosate
use in the age-adjusted analysis, which dimin-
ished slightly upon further adjustment.
Adjusted risk estimates for colon, rectum, kid-
ney, and bladder cancers were elevated by
30–60%, but these estimates were not statisti-
cally signiﬁcant. There was more than 2-fold
increased risk of multiple myeloma associated
with ever use of glyphosate in adjusted analy-
ses, although this is based on a small number
of cases. The association between myeloma
incidence and glyphosate exposure was consis-
tent in both states (ever used glyphosate, fully
adjusted analyses: Iowa RR = 2.6; North
Carolina RR = 2.7).
Results from analyses of tertiles of increas-
ing glyphosate exposure level are presented in
Table 3. A decreased risk of lung cancer was
suggested for the highest tertile of both cumu-
lative and intensity-weighted exposure days
(p-value for trend = 0.02); however, a similar
trend was not observed in analyses using never
exposed as the referent (results not shown).
There was a 40% increased risk of colon can-
cer for the highest tertile of intensity-weighted
exposure; however, no clear monotonic trend
was observed for either exposure metric.
Elevated risks of leukemia and pancreas cancer
were observed only for the middle tertiles of
both cumulative and intensity-weighted expo-
sure days, with no increased risk among those
with the highest exposure. The associations we
observed in the analysis of ever use of
glyphosate (Table 2) for melanoma, rectum,
kidney, and bladder cancers were not con-
ﬁrmed in analyses based on exposure-day met-
rics; similarly, no exposure–response patterns
were observed in analyses using never exposed
as the referent or in analyses across quintiles of
exposure (results not shown). No association
was observed between NHL and glyphosate
exposure in any analysis, including an analysis
comparing the highest with the lowest quintile
of exposure (> 108 vs. > 0–9 cumulative expo-
sure days: RR = 0.9; 95% CI, 0.4–2.1).
Elevated RRs were estimated for multiple
myeloma, with an approximate 2-fold increased
risk for the highest tertile of both cumulative
and intensity-weighted exposure days (Table 3);
however, small numbers precluded precise
effect estimation (n = 19 in adjusted analyses of
exposure-day metrics). The estimated intensity-
level component of the intensity-weighted
exposure-day metric was not associated with
multiple myeloma (highest vs. lowest tertile:
RR = 0.6; 95% CI, 0.2–1.8), and observed pos-
itive associations of the intensity-weighted
exposure-day metric with myeloma relied solely
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Table 2. Association of glyphosate exposure (ever/never used) with common cancersa among AHS
applicators.
RR (95% CI)b 
Adjusted for age,
Ever used Effect estimates demographic and
Total no. glyphosate adjusted for age lifestyle factors,
Cancer site of cancersc (% of total) (n = 54,315)d and other pesticidesd
All cancers 2,088 73.6 1.0 (0.9–1.1) 1.0 (0.9–1.2)
Lung 204 72.1 1.0 (0.7–1.3) 0.9 (0.6–1.3)
Oral cavity 59 76.3 1.1 (0.6–2.0) 1.0 (0.5–1.8)
Colon 174 75.3 1.1 (0.8–1.6) 1.4 (0.8–2.2)e
Rectum 76 77.6 1.2 (0.7–2.1) 1.3 (0.7–2.3)
Pancreas 38 76.3 1.2 (0.6–2.5) 0.7 (0.3–2.0)e
Kidney 63 73.0 1.0 (0.6–1.7) 1.6 (0.7–3.8)e
Bladder 79 76.0 1.2 (0.7–2.0) 1.5 (0.7–3.2)e
Prostate 825 72.5 1.0 (0.8–1.1) 1.1 (0.9–1.3)
Melanoma 75 84.0 1.8 (1.0–3.4) 1.6 (0.8–3.0)
All lymphohematopoietic cancers 190 75.3 1.1 (0.8–1.5) 1.1 (0.8–1.6)
NHL 92 77.2 1.2 (0.7–1.9) 1.1 (0.7–1.9)
Leukemia 57 75.4 1.1 (0.6–2.0) 1.0 (0.5–1.9)
Multiple myeloma 32 75.0 1.1 (0.5–2.4) 2.6 (0.7–9.4)f
aCancers for which at least 30 subjects had sufﬁcient information for inclusion in age-adjusted analyses. bRRs and 95%
CIs from Poisson regression models. cFrequencies among subjects included in age-adjusted analyses. dNumbers of sub-
jects in these analyses are lower than in age-adjusted analyses because of missing observations for some covariates
(models adjusted for demographic and lifestyle factors include 49,211 subjects; models additionally adjusted for other
pesticides include 40,719 subjects). eEstimates adjusted for other pesticides are shown because inclusion of other pesti-
cide variables in the model changed the effect estimate for glyphosate by at least 20%. fThe estimate for myeloma was
not confounded by other pesticides according to our change-in-estimate rule of ≥ 20%; however, the fully adjusted esti-
mate is shown for the purpose of comparison with state-speciﬁc estimates (in the text), which were confounded by other
pesticides and required adjustment.on the exposure-day component; therefore,
only results for cumulative exposure days are
shown further. When using never exposed as
the referent, the association between glyphosate
use and multiple myeloma was more pro-
nounced, with more than 4-fold increased risk
associated with the highest tertile of cumulative
exposure days (tertile 1: RR  = 2.3; 95% CI,
0.6–8.9; tertile 2: RR = 2.6; 95% CI, 0.6–11.5;
tertile 3: RR = 4.4; 95% CI, 1.0–20.2; p-value
for trend = 0.09). Although the myeloma cases
were sparsely distributed in analyses of quartiles
and quintiles, the highest increased risks were
observed in the highest exposure categories (full
set of results not shown: upper quartile vs.
never exposed: RR = 6.6; 95% CI, 1.4–30.6;
p-value for trend across quartiles = 0.01).
Discussion
There was no association between glyphosate
exposure and all cancer incidence or most of
the specific cancer subtypes we evaluated,
including NHL, whether the exposure metric
was ever used, cumulative exposure days, or
intensity-weighted cumulative exposure days.
The most consistent ﬁnding in our study was
a suggested association between multiple
myeloma and glyphosate exposure, based on a
small number of cases.
Although our study relied on self-reported
exposure information, farmers have been
shown to provide reliable information regard-
ing their personal pesticide use (Blair et al.
2002; Blair and Zahm 1993; Duell et al. 2001;
Engel et al. 2001; Hoppin et al. 2002).
Investigators have used pesticide supplier
reports (Blair and Zahm 1993) and self-
reported pesticide use information provided
earlier (Engel et al. 2001) to assess the validity
of retrospectively reported pesticide use data.
Among farmers in the AHS, Blair et al. (2002)
reported high reliability for reports of ever use
of a particular pesticide (ranging from 70 to
> 90%). Agreement for duration and fre-
quency of use was lower but generally 50–60%
for specific pesticides. Hoppin et al. (2002)
have demonstrated that farmers provide plausi-
ble data regarding lifetime duration of use,
with fewer than 5% reporting implausible val-
ues for speciﬁc chemicals.
There were rather few cases of NHL for
inclusion in this analysis (n = 92); nevertheless,
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Table 3. Association of glyphosate exposure (cumulative exposure days and intensity-weighted exposure days) with common cancersa among AHS applicators.
Cumulative exposure daysb Intensity-weighted exposure daysc
Tertile Tertile
Cancer site cut points No. RR (95% CI)d p-Trend cut points No. RR (95% CI)d p-Trend
All cancers 1–20 594 1.0 0.1–79.5 435 1.0
21–56 372 1.0 (0.9–1.1) 79.6–337.1 436 0.9 (0.8–1.0)
57–2,678 358 1.0 (0.9–1.1) 0.57 337.2–18,241 438 0.9 (0.8–1.1) 0.35
Lung 1–20 40 1.0 0.1–79.5 27 1.0
21–56 26 0.9 (0.5–1.5)e 79.6–337.1 38 1.1 (0.7–1.9)e
57–2,678 26 0.7 (0.4–1.2)e 0.21 337.2–18,241 27 0.6 (0.3–1.0)e 0.02
Oral cavity 1–20 18 1.0 0.1–79.5 11 1.0
21–56 10 0.8 (0.4–1.7) 79.6–337.1 14 1.1 (0.5–2.5)
57–2,678 10 0.8 (0.4–1.7) 0.66 337.2–18,241 13 1.0 (0.5–2.3) 0.95
Colon 1–20 32 1.0 0.1–79.5 25 1.0
21–56 28 1.4 (0.9–2.4)e 79.6–337.1 20 0.8 (0.5–1.5)c
57–2,678 15 0.9 (0.4–1.7)e 0.54 337.2–18,241 30 1.4 (0.8–2.5)c 0.10
Rectum 1–20 20 1.0 0.1–79.5 16 1.0
21–56 17 1.3 (0.7–2.5) 79.6–337.1 18 1.0 (0.5–2.0)
57–2,678 14 1.1 (0.6–2.3) 0.70 337.2–18,241 16 0.9 (0.5–1.9) 0.82
Pancreas 0–20 9 1.0 0–79.5 6 1.0
21–56 9 1.6 (0.6–4.1) 79.6–337.1 16 2.5 (1.0–6.3)
57–2,678 7 1.3 (0.5–3.6) 0.83 337.2–18,241 3 0.5 (0.1–1.9) 0.06
Kidney 1–20 20 1.0 0.1–79.5 20 1.0
21–56 8 0.6 (0.3–1.4) 79.6–337.1 7 0.3 (0.1–0.7)
57–2,678 9 0.7 (0.3–1.6) 0.34 337.2–18,241 10 0.5 (0.2–1.0) 0.15
Bladder 1–20 23 1.0 0.1–79.5 14 1.0
21–56 14 1.0 (0.5–1.9) 79.6–337.1 8 0.5 (0.2–1.3)
57–2,678 17 1.2 (0.6–2.2) 0.53 337.2–18,241 13 0.8 (0.3–1.8) 0.88
Prostate 1–20 239 1.0 0.1–79.5 167 1.0
21–56 132 0.9 (0.7–1.1) 79.6–337.1 169 1.0 (0.8–1.2)
57–2,678 145 1.1 (0.9–1.3) 0.69 337.2–18,241 174 1.1 (0.9–1.3) 0.60
Melanoma 1–20 23 1.0 0.1–79.5 24 1.0
21–56 20 1.2 (0.7–2.3) 79.6–337.1 16 0.6 (0.3–1.1)
57–2,678 14 0.9 (0.5–1.8) 0.77 337.2–18,241 17 0.7 (0.3–1.2) 0.44
All lymphohematopoietic cancers 1–20 48 1.0 0.1–79.5 38 1.0
21–56 38 1.2 (0.8–1.8) 79.6–337.1 40 1.0 (0.6–1.5)
57–2,678 36 1.2 (0.8–1.8) 0.69 337.2–18,241 43 1.0 (0.7–1.6) 0.90
NHL 1–20 29 1.0 0.1–79.5 24 1.0
21–56 15 0.7 (0.4–1.4) 79.6–337.1 15 0.6 (0.3–1.1)
57–2,678 17 0.9 (0.5–1.6) 0.73 337.2–18,241 22 0.8 (0.5–1.4) 0.99
Leukemia 1–20 9 1.0 0.1–79.5 7 1.0
21–56 14 1.9 (0.8–4.5)e 79.6–337.1 17 1.9 (0.8–4.7)e
57–2,678 9 1.0 (0.4–2.9)e 0.61 337.2–18,241 8 0.7 (0.2–2.1)e 0.11
Multiple myeloma 1–20 8 1.0 0–79.5 5 1.0
21–56 5 1.1 (0.4–3.5)e 79.6–337.1 6 1.2 (0.4–3.8)e
57–2,678 6 1.9 (0.6–6.3)e 0.27 337.2–18,241 8 2.1 (0.6–7.0)e 0.17
aCancers for which at least 30 subjects had sufﬁcient information for inclusion in age-adjusted analyses. bNumbers of subjects in analyses vary depending on missing observations for
cumulative exposure days and some covariates (models adjusted for demographic and lifestyle factors include 36,823 subjects; models additionally adjusted for other pesticides include
30,699 subjects). cNumbers of subjects in analyses vary depending on missing observations for intensity-weighted cumulative exposure days and some covariates (models adjusted for
demographic and lifestyle factors include 36,509 subjects; models additionally adjusted for other pesticides include 30,613 subjects). dRelative rate ratios and 95% CIs from Poisson
regression analyses. eEstimates adjusted for other pesticides are shown because inclusion of other pesticide variables in the model changed the effect estimate for glyphosate by at
least 20%.the available data provided evidence of no
association between glyphosate exposure and
NHL incidence. This conclusion was consis-
tent across analyses using the different expo-
sure metrics and in analyses using either never
exposed or low exposed as the referent.
Furthermore, there was no apparent effect of
glyphosate exposure on the risk of NHL in
analyses stratified by state of residence or in
analyses of highly exposed groups comparing
the highest with the lowest quintile of expo-
sure. These ﬁndings conﬂict with recent stud-
ies. The first report of an association of
glyphosate with NHL was from a case–control
study, but the estimate was based on only four
exposed cases (Hardell and Eriksson 1999).
A pooled analysis of this initial study with a
study of hairy cell leukemia showed a relation-
ship between glyphosate exposure and an
increased risk of disease [unadjusted analysis:
odds ratio (OR) = 3.0; 95% CI, 1.1–8.5]
(Hardell et al. 2002). A more extensive study
conducted across a large region of Canada
found an elevated risk of NHL associated with
glyphosate use more frequent than 2 days/year
(OR = 2.1; 95% CI, 1.2–3.7) (McDufﬁe et al.
2001). Similarly, increased NHL risk in men
was associated with having ever used
glyphosate (OR = 2.1; 95% CI, 1.1–4.0) after
adjustment for other commonly used pesti-
cides in a pooled analysis of National Cancer
Institute–sponsored case–control studies con-
ducted in Nebraska, Kansas, Iowa, and
Minnesota (De Roos et al. 2003b). These pre-
vious studies were retrospective in design and
thereby potentially susceptible to recall bias of
exposure reporting. Our analysis of the AHS
cohort had a prospective design, which should
largely eliminate the possibility of recall bias.
Differences in recall bias could account for
discrepant study results; however, evaluation
of the potential for recall bias in case–control
studies of pesticides among farmers has not
uncovered evidence that it occurred (Blair and
Zahm 1993).
Our ﬁnding of a suggested association of
multiple myeloma incidence with glyphosate
exposure has not been previously reported,
although numerous studies have observed
increased myeloma risk associated with farm-
ing occupation (Boffetta et al. 1989; Brownson
et al. 1989; Cantor and Blair 1984; Cerhan
et al. 1998; Cuzick and De Stavola 1988;
Eriksson and Karlsson 1992; Figgs et al. 1994;
Gallagher et al. 1983; La Vecchia et al. 1989;
Nandakumar et al. 1986, 1988; Pasqualetti
et al. 1990; Pearce et al. 1985; Pottern et al.
1992; Reif et al. 1989; Vagero and Persson
1986). A possible biologic mechanism of how
glyphosate might act along the causal pathway
of this plasma cell cancer has not been hypoth-
esized, but myeloma has been associated with
agents that cause either DNA damage or
immunosuppression (De Roos et al. 2003a).
The association we observed was with ever use
of glyphosate and cumulative exposure days of
use (a combination of duration and fre-
quency), but not with intensity of exposure.
Estimated intensity of glyphosate exposure
was based on general work practices that were
not glyphosate speciﬁc, including the percent-
age of time spent mixing and applying pesti-
cides, application method, use of personal
protective equipment, and repair of pesticide
application equipment (Dosemeci et al. 2002).
Information on work practices specific to
glyphosate use would clarify whether intensity
of exposure contributes to myeloma risk.
The number of myeloma cases in our study
was small, and it is plausible that spurious asso-
ciations arose by chance; however, several
aspects of our results argue against a chance
association. The ﬁndings were internally con-
sistent, with increased risk observed in both
states. Adding to the credibility of the associa-
tion, there was some indication of a dose–
response relationship, with risk estimates
increasing across categories of increasing expo-
sure and stronger associations observed when
using never-exposed subjects as the referent (as
opposed to low exposed). Another possible
explanation for spurious associations is unad-
justed confounding. Our risk estimates were
adjusted for some demographic and lifestyle
factors and other pesticides. Of the other pesti-
cides included in the fully adjusted model, only
diazinon and triﬂuralin were important con-
founders of the glyphosate–myeloma associa-
tion. It is certainly possible that an unknown
risk factor for myeloma could have con-
founded our results; however, any unknown
confounder would have to be linked with
glyphosate use. Finally, the increased myeloma
risk associated with glyphosate use could be
due to bias resulting from a selection of sub-
jects in adjusted analyses that differed from
subjects included in unadjusted analyses.
Table 1 shows that 54,315 subjects were
included in age-adjusted models, whereas
because of missing data for covariates, only
40,719 subjects were included in fully adjusted
analyses. The association of glyphosate with
myeloma differed between the two groups,
even without adjustment for any covariates,
with no association among the full group and a
positive association among the more restricted
group. Subjects who answered all the questions
and were thus included in adjusted analyses
differed from those who dropped out of such
analyses in that they were more likely to be
from Iowa (71.8% in included group vs.
44.6% in dropped group), were younger (aver-
age age, 51.5 vs. 57.9 years), and were more
highly educated (46.7% educated beyond high
school graduate vs. 30.2%); however, the two
groups were similar in their use of glyphosate
(75.9% vs. 74.5%). The increased risk associ-
ated with glyphosate in adjusted analyses may
be due to selection bias or could be due to a
confounder or effect modifier that is more
prevalent among this restricted subgroup and is
unaccounted for in our analyses. Further fol-
low-up of the cohort and reevaluation of the
association between glyphosate exposure and
myeloma incidence after a greater number of
cases develop will allow more detailed exami-
nation of the potential biases underlying the
association.
Certain limitations of our data hinder the
inferences we can make regarding glyphosate
and its association with specific cancer sub-
types. Although the AHS cohort is large, and
there were many participants reporting
glyphosate use, the small numbers of speciﬁc
cancers occurring during the follow-up period
hindered precise effect estimation. In addi-
tion, most applicators were male, precluding
our ability to assess the association between
glyphosate exposure and cancer incidence
among women, for both non-sex-specific
cancers and sex-specific cancers (e.g., of the
breast or ovary). Our analysis provides no
information on the timing of pesticide use in
relation to disease, limiting the ability to sufﬁ-
ciently explore latency periods or effects result-
ing from glyphosate exposure at different ages.
Despite limitations of our study, certain infer-
ences are possible. This prospective study of
cancer incidence provided evidence of no asso-
ciation between glyphosate exposure and most
of the cancers we studied, and a suggested asso-
ciation between glyphosate and the risk of mul-
tiple myeloma. Future analyses within the AHS
will follow up on these ﬁndings and will exam-
ine associations between glyphosate exposure
and incidence of less common cancers.
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